Key Developments: Fresenius SE & Co KGaA (FREG.DE)

FREG.DE on Xetra

107.10EUR
17 Apr 2014
Price Change (% chg)

€-0.05 (-0.05%)
Prev Close
€107.15
Open
€106.85
Day's High
€107.50
Day's Low
€106.05
Volume
345,210
Avg. Vol
445,284
52-wk High
€120.60
52-wk Low
€87.03

Search Stocks

Latest Key Developments (Source: Significant Developments)

Fresenius SE & Co KGaA to issue 375 million euros convertible bond - Reuters
Tuesday, 18 Mar 2014 02:40am EDT 

Fresenius SE & Co KGaA:Announces issuance of equity-neutral convertible bonds - Reuters.To issue 375 million euros equity-neutral convertible bonds due 2019.  Full Article

Fresenius SE & Co KGaA issues FY 2014 outlook and proposes FY 2013 dividend
Tuesday, 25 Feb 2014 01:00am EST 

Fresenius SE & Co KGaA:Projects sales growth of 12 pct to 15 pct in constant currency for FY 2014.FY 2013 sales of 20,331 million euro.FY 2014 revenue of 23,100 million euro - Thomson Reuters I/B/E/S.Expects net income attributable to shareholders to increase in FY 2014 by 2 to 5 pct in constant currency.Will propose a dividend increase of 14 pct to 1.25 euro per share for FY 2013.FY 2012 dividend was of 1.10 euro per share.  Full Article

German Cartel Office grants merger control clearance to Rhoen Klinikum AG for transaction with Fresenius/HELIOS
Thursday, 20 Feb 2014 07:18am EST 

Rhoen Klinikum AG:Announces that the German Cartel Office, granted merger control clearance for the transaction with Fresenius/HELIOS without restrictions and conditions.The merger control clearance comprises 40 clinics, medical centers and related companies and thus the entire sold portfolio except for the clinics in Cuxhaven, Waltershausen-Friedrichroda und Boizenburg and two management companies for medical centers.The excepted companies were, in coordination with the Cartel Office, removed from the sold portfolio already prior to the merger control clearance.The cleared transaction will for the most part be closed until end of Feb. by payment of the purchase price and transfer of the shares.  Full Article

Fresenius SE & Co KGaA Acquires 43 Hospitals and Fifteen Outpatient Facilities from Rhoen-Klinikum AG
Thursday, 12 Sep 2013 08:52pm EDT 

Fresenius SE & Co KGaA announced that it has signed a binding agreement to purchase the majority of Rhoen-Klinikum AG's hospitals, acquiring 43 hospitals with a total of approximately 11,800 beds as well as fifteen outpatient facilities. The purchase price of EUR 3.07 billion will be entirely debt-financed. Under the transaction, Fresenius will not assume any financial debt of Rhoen-Klinikum AG.  Full Article

Fresenius SE & Co KGaA Raises FY 2013 Guidance
Tuesday, 30 Jul 2013 12:59am EDT 

Fresenius SE & Co KGaA announced that it raises its full fiscal year 2013 earnings guidance, and thus expects net income to increase by 11% to 14% in constant currency. Previously, Fresenius expected fiscal year 2013 net income growth of 7% to 12% in constant currency. The Company fully confirms its fiscal year 2013 sales guidance, with sales expected to increase by 7% to 10% in constant currency.  Full Article

China Probes Pricing At Drugmakers Including Fresenius SE & Co KGaA-Reuters
Thursday, 4 Jul 2013 07:31am EDT 

Reuters reported that China's top economic planning agency is investigating costs and prices charged by drugmakers, including units of GlaxoSmithKline and Merck & Co Inc, as foreign firms come under pressure from Beijing over possible price-fixing. The move follows a separate probe into instant milk powder, which has already led to price cuts. The National Development and Reform Commission (NDRC) is surveying production costs and prices charged at multiple foreign and Chinese drug companies, according to a July 2, 2013 statement from the commission. News of the investigation was reported earlier on Thursday by the official Securities Daily newspaper. The NDRC will examine 27 companies on cost issues and 33 for pricing. The investigation is being done to understand the cost and pricing situation within the companies, and to adjust drug prices in a timely manner, the agency said. In addition to GSK and Merck, other foreign companies being investigated over costs include Astellas Pharma Inc, Novartis AG's generics unit Sandoz, Boehringer Ingelheim, Baxter International Inc and Fresenius SE & Co KGaA. An investigation team from NDRC will visit the companies involved between July and October, the agency said.  Full Article

Fresenius SE & Co KGaA Comments on FY 2013 Sales Growth
Tuesday, 26 Feb 2013 01:07am EST 

Fresenius SE & Co KGaA announced that it expects group sales growth of 7% to 10% in the fiscal year 2013.  Full Article

Fresenius SE & Co KGaA To Quit Biotech Unit-Reuters
Friday, 14 Dec 2012 02:15am EST 

Reuters reported that Fresenius SE & Co KGaA will exit its loss-making biotech business in order to focus on its other businesses. Fresenius said it was in talks with several parties over a sale of Fresenius Biotech, which had sales of EUR26 million ($34 million) in the first nine months of 2012 but posted a loss of EUR15 million.  Full Article

Fresenius SE & Co KGaA Drops Plans To Buy Rhoen-Klinikum AG-Reuters
Sunday, 2 Sep 2012 08:57am EDT 

Reuters reported that Fresenius SE & Co KGaA has dropped plans to renew its EUR3.1 billion offer for Rhoen-Klinikum German paper Die Welt reported.  Full Article

Fresenius SE & Co KGaA.'s Fresenius Kabi AG Acquires Fenwal Holdings, Inc.
Thursday, 19 Jul 2012 08:00pm EDT 

Fresenius Kabi AG, a 100% subsidiary of Fresenius SE & Co. KGaA., announced that it has signed a definitive agreement to acquire Fenwal Holdings, Inc., a U.S.-based provider of transfusion technology products for blood collection, separation and processing, from TPG and Maverick Capital. Financial terms were not disclosed. The transaction will be financed initially from existing funds, whereas the enterprise value does not exceed the proceeds of the May 2012 capital increase. Irrespective of acquiring Fenwal, Fresenius continues to assess its options for an acquisition of Rhön-Klinikum AG. The transaction is subject to the necessary regulatory approvals by the relevant antitrust authorities, and is expected to close at the end of 2012.  Full Article

Rhoen CFO says eyeing acquisition of larger hospitals - paper

FRANKFURT, April 10 - German hospitals operator Rhoen-Klinikum, which has sold about two thirds of its assets to peer Fresenius, is looking for takeover targets to focus on larger hospital complexes.

Search Stocks